AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01552291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: 30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
Study NCT01552291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30g oral maltodextrin / day for 5 days before surgery
Study NCT01794611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscopy
Study NCT01379469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug-Carbamazepine (Tegretol XR)
Description: To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated..
Study NCT01379469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbamazepine (Tegretol XR) Placebo
Description: Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
Study NCT01666431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib
Study NCT00432042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad®
Description: Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).
Study NCT00432042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad®
Description: Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).
Study NCT00432042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix® hexa
Description: Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
Study NCT00432042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix® hexa
Description: Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
Study NCT02287389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilation
Study NCT02287389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Study NCT02287389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spiculiform electrosurgery
Study NCT02287389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Study NCT00763750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPX +TMZ+XRT
Description: PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
Study NCT02648802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cavity shaving
Description: Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
Study NCT04299607 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DPP Fever Panel II assay and DPP Micro Readers
Description: Detection of common causes of acute febrile illnesses in Asia
Study NCT01238926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PD vitamin supplementation
Description: 25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
Study NCT01238926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD exercise intervention
Description: Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
Study NCT01238926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD vitamin + exercise
Description: 25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum \[RM\]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
Study NCT02648802 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardized BCS+CM assessment.
Description: For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
Study NCT02648802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized BCS+CM assessment.
Description: For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
Study NCT02467738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo brachytherapy with Cesium-131
Study NCT02467738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesium-131
Description: Undergo brachytherapy with Cesium-131
Study NCT02467738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Undergo surgical resection
Study NCT02009436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given via nebulizer
Study NCT02009436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02009436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01294202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387 and Imatinib
Description: In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib.
Study NCT02073175 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
Study NCT02073175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motherwell
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
Study NCT02976714 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: spontaneous sputum
Description: CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate.
Study NCT01922687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine plus atorvastatin (Caduet)
Study NCT01922687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine (Norvasc)
Study NCT00642395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: bortezomib-Melphalan
Study NCT02215876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
Study NCT02215876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
Study NCT02215876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
Study NCT03309085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated CT scan
Description: CT scan of chest on different PEEP levels, 4 in total
Study NCT03309085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan
Study NCT01268358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: Lamazym, ERT, infusion weekly
Study NCT01981655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5M Sodium lactate
Description: A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
Study NCT01981655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's solution
Description: Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
Study NCT02533063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VibeTech One
Description: Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g.
Study NCT02533063 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VibeTech One
Description: Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g.
Study NCT02595476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT02595476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study NCT02595476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT02595476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study NCT02595476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCI
Study NCT02595476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCI
Study NCT02595476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tetanic stimulation
Study NCT02595476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation
Study NCT02595476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algiscan
Description: Pupillometry
Study NCT02595476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algiscan
Description: Pupillometry
Study NCT03850600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet-CD
Description: CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
Study NCT02532881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos
Description: Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
Study NCT02532881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT02532881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT03754621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum thyroid functions tests
Description: Serum TSH, fT3, fT4 and anti-TPO
Study NCT00793897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
Study NCT00793897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
Study NCT00793897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
Study NCT03383484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
Study NCT03383484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
Study NCT00530985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits Counseling
Description: Help deciding whether to work
Study NCT00530985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Orientation
Description: Orientation to services available at VA
Study NCT00071942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-MUC1 vaccine
Description: Given intradermally
Study NCT00071942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-TRICOM vaccine
Description: Given intradermally
Study NCT00071942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00071942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02701452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COAGO
Description: blood samples for haemostasis and hormonal data
Study NCT03728075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES was placed on the quadriceps muscle of both legs
Study NCT06190652 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy combined with immunotherapy
Description: chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
Study NCT06190652 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy
Description: Intensity-modulated radiation therapy
Study NCT01859728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.
Study NCT01859728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.
Study NCT01859728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics.
Study NCT01859728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics.
Study NCT03804203 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions
Study NCT03804203 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study NCT03885310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GIE Drug Coated Balloon
Description: The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
Study NCT03691129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participation in the elderly yoga program
Description: Yoga participant groups will practice elderly yoga for four months.
Study NCT05818592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Pulse Monitoring
Description: Participants will manually monitor pulse for irregularities.
Study NCT02427074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Compression Rhizotomy
Description: The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
Study NCT02427074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Thermal Coagulation Rhizotomy
Description: The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
Study NCT01027819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile bearing
Description: Mobile bearing in total knee arthroplasty
Study NCT01027819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed bearing
Description: Fixed bearing in total knee arthroplasty